15th Residential Course on Clinical Pharmacology of Antiretrovirals

January 15-17, 2020

Starhotels Majestic, corso Vittorio Emanuele II 54, Turin

www.fcarvturin.it
COURSE RATIONALE
Rapid advances in disease management require the ongoing attention of healthcare professionals. This course will address the implications of new PK/PD information on strategies for clinical management of patients with HIV, HBV and HCV infections.
Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert panel of clinicians and researchers. The three-day course will bring together researchers and clinicians from various parts of the world to discuss pro and cons of current PK/PD strategies in anti-infective area. Each topic focuses on preclinical, translational and clinical aspects and will provide opportunity for discussion and input from the audience. This meeting will be a valuable experience for all involved in infectious diseases, as researchers or prescribers of anti-infective agents.

LEARNING OBJECTIVES
Participants will be taught on learning goals:
• Recognize the role of PK/PD parameters for the management of HIV, HBV and HCV infections.
• Focus on recent developments regarding PK variability of antivirals and its association with specific tissue drug penetration and clearance.
• Describe the challenges of HIV, HBV and HCV treatment as it relates to cure and selection of drug resistance.
• Develop strategies to modify HIV and anti-hepatitis treatment regimens based on individual patient response.
• Devise a plan to manage drug interactions and adverse effects of HIV, HBV and HCV treatments and optimize treatment responses.
• Present real and typical clinical scenarios, discuss findings and management in the light of current PK/PD data and clinical practices guidelines.
15th Residential Course on Clinical Pharmacology of Antiretrovirals

January 15-17, 2020

COURSE DIRECTOR
Prof. G. Di Perri
Head of the Department of Infectious Diseases, University of Turin, Italy

SCIENTIFIC SECRETARIAT
S. Bonora, A. Calcagno
Department of Infectious Diseases, University of Turin, Italy
Phone: +39 011 4393980/4393867, Fax: +39 011 4393882
E-mail: stefano.bonora@unito.it - andrea.calcagno@unito.it
C. Alcantarini, Department of Medical Sciences, University of Turin, Italy.

M. Andreoni, Department of Infectious Diseases, University “Tor Vergata”, Rome, Italy.

A. Antinori, Department of Infectious Diseases, IRCCS “Lazzaro Spallanzani”, Rome, Italy.

D. Back, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

M. Boffito, Chelsea and Westminster Hospital, London, UK.

L. Boglione, Department of Infectious Diseases, University of Turin, Italy.

S. Bonora, Department of Medical Sciences, University of Turin, Italy.

M.R. Brunetto, Gastroenterology Unit, Hospital and University of Pisa, Italy.

R. Bruno, Institute of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

D. Burger, Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre, Nijmegen, The Netherlands.

A. Calcagno, Department of Medical Sciences, University of Turin, Italy.

D. Cattaneo, Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

F. Ceccherini-Silberstein, Virology Unit, University “Tor Vergata”, Rome, Italy.

A. Cherubini, Geriatrics, Geriatric Emergency care and Center for research on aging, IRCCS INRCA, Ancona, Italy.

A. Ciancio, Department of Gastroenterology, University of Turin, Italy.

A. D'Avolio, Department of Infectious Diseases, University of Turin, Italy.

F.G. De Rosa, Department of Infectious Diseases, University of Turin, Italy.

G. Di Perri, Department of Medical Sciences, University of Turin, Italy.

M. Ferrara, Department of Medical Sciences, University of Turin, Italy.

C.V. Fletcher, Departments of Pharmacy Practice and Division of Infectious Diseases, Department of Internal Medicine at the University of Nebraska Medical Center, USA.

M. Galli, Department of Infectious Diseases, University of Milan, Italy.
R. Garraffo, Pharmacology Laboratory, CHU Pasteur, Nice, France.

V. Ghisetti, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.

S. Gianella Weibel, Division of Infectious Diseases, University of California, San Diego, La Jolla, CA, USA.

S. Khoo, Department of Pharmacology & Therapeutics, University of Liverpool, UK.

M. Lamorde, Prevention Care and Treatment Department, Infectious Diseases Institute, Makerere University Kampala, Uganda.

S. Letendre, Departments of Medicine and Psychiatry, University of California San Diego, San Diego, CA, USA.

Q. Ma, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical sciences, University at Buffalo, USA.

G. Marchetti, Department of Health Sciences, San Paolo Hospital – University of Milan, Italy.

C. Marzolini, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.

J. Moltò, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.

C. Mussini, Institute of Infectious Diseases, University of Modena, Italy.

G. Nunnari, Institute of Infectious Diseases, University of Messina, Italy.

A. Owen, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

B. Palmer, Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado, USA.

C.F. Perno, Department of Health Sciences, Institute of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

M. Puoti, Infectious Diseases Unit, “Niguarda Ca' Granda” Hospital, Milan, Italy.

D. Ripamonti, Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

M. Siccardi, Department of Pharmacology & Therapeutics, University of Liverpool, UK.
WEDNESDAY JAN 15 - AFTERNOON SESSION
13:30 CME registration and welcome lunch
14:30 Welcome and introduction (G. Di Perri, S. Bonora, A. Calcagno)
SESSION I - MANAGEMENT OF POLYPHARMACY AND DDIs (Chair: D. Back, R. Garraffo)
15:00 Deprescribing: the fightback against polypharmacy (C. Marzolini)
15:30 Lesson from Geriatrics: the SENATOR experience (A. Cherubini)
16:00 Multidisciplinary experience to manage polypharmacy in the clinical setting (D. Cattaneo)
16:30 A new tool to share clinical experiences of DDIs management (J. Moltò)
17:00 Coffee break
17:30 Plasma measurement of antivirals in the clinical setting: which role in 2020? (D. Burger)
18:00 Case-based interactive discussion (M. Ferrara, C. Alcantarini)
18:30 Closing Day 1 Remarks

THURSDAY JAN 16 - MORNING SESSIONS
SESSION II - TWO-DRUG REGIMENS FOR HIV INFECTION (Chair: C. Mussini, A. Antinori)
9:00 Pros and Cons from clinical trials (D. Ripamonti)
9:30 Clinical pharmacology of two-drug regimens (G. Di Perri)
10:00 The virology of two-drug regimens and the tale of the reservoir (C. F. Perno)
10:30 Coffee break
SESSION III - INSIGHTS ON CLINICAL PHARMACOLOGY OF NEW AND UPCOMING ARVs
(Chair: M. Galli, M. Andreoni)
11:00 New NRTIs and NNRTIs (S. Bonora)
11:30 New INIs (G. Di Perri)
12:00 New entry inhibitors and new drug classes (S. Khoo)
12:30 Broadly neutralizing antibodies (bNAbS) against HIV (Q. Ma)
13:00 Lunch
THURSDAY JAN 16 - AFTERNOON SESSIONS

SESSION IV - DRUGS IN TRANSITION (Chair: A. Calcagno)
14:00 Transition to new antivirals in low and middle-income countries (M. Lamorde)

SESSION V - NEWS FROM THE RESERVOIRS (Chair: G. Nunnari, V. Ghisetti)
14:30 Adipose tissue (S. Gianella Weibel)
15:00 Lymphatic tissue (C. Fletcher)
15:30 Olfactory mucosa (A. Calcagno)
16:00 Coffee break
16:30 Central Nervous System (S. Letendre)
17:00 Gut and inflammation (G. Marchetti)
17:30 Microbiome in HIV: chronic inflammation, immune activation and transmission (B. Palmer)
18:00 Closing Day 2 Remarks

FRIDAY JAN 17 - MORNING SESSIONS

SESSION VI - VIRAL HEPATITIS AND BEYOND (Chair: A. Ciancio, F. Ceccherini-Silberstein)
9:00 HCV the road to “elimination”: drugs and strategies (M. Puotì)
9:30 Pharmacological treatment of NASH (R. Bruno)
10:00 Novel targets and strategies to cure HBV (M. Brunetto)
10:30 Case-based interactive discussion: extra-hepatic manifestations beyond cure (L. Boglione)
11:00 Coffee break

SESSION VII - SHORT WAY TO LONG ACTING AGENTS FOR INFECTIOUS DISEASES
(Chair: S. Bonora, A. D’Avolio)
11:30 Improving long acting delivery (A. Owen)
12:00 Clinical pharmacology of long acting agents for HIV prevention and treatment (M. Boffito)
12:30 Long-acting antimicrobial agents: current status and perspectives (F.G. De Rosa)
13:00 Long acting agents for tuberculosis (M. Siccardi)
13:30 Course Closing Remarks (G. Di Perri)
13:45 CME test
CONGRESS INFORMATION

● SCIENTIFIC SECRETARIAT
S. Bonora, A. Calcagno, Department of Medical Sciences, University of Turin, Italy
Phone: +39 011 4393980 / 4393867 - Fax: +39 011 4393882
E-mail: stefano.bonora@unito.it; andrea.calcagno@unito.it

● TARGET AUDIENCE AND CME CREDITS
Provider HealthData Consulting s.r.l. (n.546) has assigned 14 CME credits according to Italian Health Ministry's criteria. CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: physicians, hospital pharmacists and biologists. The course is designed for healthcare professionals who are actively involved in the medical care of people with HIV, HBV and HCV infection.

● DATES AND SCHEDULE
January 15-17, 2020
Wednesday (14:30-18:30); Thursday (09:00-18:00); Friday (09:00-13:45)

● LANGUAGE
The official language of the Course is English. There is no simultaneous interpretation.

● COURSE WEBSITE
Updated information will be found on the course website, www.fcarvturin.it

● ORGANIZING SECRETARIAT & ITALIAN CME PROVIDER
HealthData Consulting S.r.l.
Via Morghen 274, Turin
Phone: +39 011 0267950 - Fax: +39 011 0267954
e-mail: segreteria@hdcons.it
web: www.hdcons.it

● COURSE LOCATION
All sessions will be held at the Starhotels Majestic
Corso Vittorio Emanuele II 54, Turin
Phone: +39 011 539153
Fax: +39 011 534963
Please see what meals are included with your registration below:

<table>
<thead>
<tr>
<th>DAY</th>
<th>MORNING BREAK</th>
<th>LUNCH</th>
<th>AFTERNOON BREAK</th>
<th>DINNER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 15th January</td>
<td><em>Not included</em></td>
<td>Starhotels Majestic*</td>
<td>Starhotels Majestic</td>
<td>Starhotels Majestic</td>
</tr>
<tr>
<td>Thursday 16th January</td>
<td>Starhotels Majestic</td>
<td>Starhotels Majestic</td>
<td>Starhotels Majestic</td>
<td>Social Dinner</td>
</tr>
<tr>
<td>Friday 17th January</td>
<td>Starhotels Majestic</td>
<td>Starhotels Majestic**</td>
<td><em>Not included</em></td>
<td><em>Not included</em></td>
</tr>
</tbody>
</table>

* Welcome lunch
** Light refreshment

A Social Dinner will be offered to the Course’s attendees.

Social Dinner is free of charge for participants, but is essential to confirm your presence. In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intolerance or allergies.
16th Residential Course on Clinical Pharmacology of Antiretrovirals

January, 2021

Starhotels Majestic, corso Vittorio Emanuele II 54, Turin